-
Something wrong with this record ?
Recurrences and bleeding during extended treatment of patients with venous thromboembolism: results of the international, prospective, observational WHITE study
G. Palareti, V. Barinov, T. Urbanek, M. Cini, YJ. Li, K. Bouslama, J. Matuška, A. Mansilha, J. Madaric, GY. Sokurenko, GM. Andreozzi, WHITE study group
Language English Country Italy
Document type Observational Study, Journal Article
- MeSH
- Anticoagulants therapeutic use MeSH
- Administration, Oral MeSH
- Fibrinolytic Agents MeSH
- Heparin, Low-Molecular-Weight adverse effects MeSH
- Hemorrhage chemically induced epidemiology MeSH
- Humans MeSH
- Prospective Studies MeSH
- Venous Thromboembolism * drug therapy epidemiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
BACKGROUND: Little data are available on real-life long-term treatments after a venous thromboembolism (VTE), and on recurrent VTE or bleeds events during treatments. METHODS: We investigated the complications occurring during follow-up (FU) in VTE patients who had received the treatment decisions given by the clinical centers, active in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, Tunisia), which participated in the international, prospective, observational WHITE study. RESULTS: FU information was collected in 1004 patients, recruited by 62 clinical centers (17 centers did not participate in FU collection). Extended treatments were proposed to 811 patients: direct oral anticoagulants (DOACs) (475), sulodexide (202), antiplatelet agents (73), vitamin K antagonists (VKAs) (45), low molecular weight heparin (LMWH) (16). All specific treatments were stopped in the remaining 193 patients. Patients who during FU used treatments different than those prescribed by the local investigators (263) or for other causes (26) were excluded from analysis. 50 primary events occurred throughout 1044 years FU in 715 patients, 4.8 incidence (×100 patient-years) [3.8 for recurrences, and 0.96 for bleeding (major or clinically relevant)]. Primary event incidence differed according to treatments (LMWH=33.3, antiplatelets =7.6, VKAs = 6.1, DOACs = 4.7, sulodexide = 4.2, all treatment stopped = 2.5), and differed across the involved countries. CONCLUSIONS: DOACs were the most used drugs for extended treatments. Overall, the rate of primary events during FU was low. The investigators identified patients at low risk of recurrence and high bleeding risk. Sulodexide use for secondary prevention deserves further studies.
Arianna Anticoagulazione Foundation Bologna Italy
Clinical Trial Centre Hodonin Czechia
Faculty of Medicine of Tunis Tunis Tunisia
Faculty of Medicine University of Porto Porto Portugal
Medical University of Silesia Katowice Poland
North West Mechnikov State Medical University St Petersburg Russia
Peking Union Medical College Chinese Academy of Medical Sciences Beijing China
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004288
- 003
- CZ-PrNML
- 005
- 20230425141249.0
- 007
- ta
- 008
- 230418s2023 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.23736/S0392-9590.22.04970-7 $2 doi
- 035 __
- $a (PubMed)36714910
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Palareti, Gualtiero $u Arianna Anticoagulazione Foundation, Bologna, Italy - gualtiero.palareti@unibo.it
- 245 10
- $a Recurrences and bleeding during extended treatment of patients with venous thromboembolism: results of the international, prospective, observational WHITE study / $c G. Palareti, V. Barinov, T. Urbanek, M. Cini, YJ. Li, K. Bouslama, J. Matuška, A. Mansilha, J. Madaric, GY. Sokurenko, GM. Andreozzi, WHITE study group
- 520 9_
- $a BACKGROUND: Little data are available on real-life long-term treatments after a venous thromboembolism (VTE), and on recurrent VTE or bleeds events during treatments. METHODS: We investigated the complications occurring during follow-up (FU) in VTE patients who had received the treatment decisions given by the clinical centers, active in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, Tunisia), which participated in the international, prospective, observational WHITE study. RESULTS: FU information was collected in 1004 patients, recruited by 62 clinical centers (17 centers did not participate in FU collection). Extended treatments were proposed to 811 patients: direct oral anticoagulants (DOACs) (475), sulodexide (202), antiplatelet agents (73), vitamin K antagonists (VKAs) (45), low molecular weight heparin (LMWH) (16). All specific treatments were stopped in the remaining 193 patients. Patients who during FU used treatments different than those prescribed by the local investigators (263) or for other causes (26) were excluded from analysis. 50 primary events occurred throughout 1044 years FU in 715 patients, 4.8 incidence (×100 patient-years) [3.8 for recurrences, and 0.96 for bleeding (major or clinically relevant)]. Primary event incidence differed according to treatments (LMWH=33.3, antiplatelets =7.6, VKAs = 6.1, DOACs = 4.7, sulodexide = 4.2, all treatment stopped = 2.5), and differed across the involved countries. CONCLUSIONS: DOACs were the most used drugs for extended treatments. Overall, the rate of primary events during FU was low. The investigators identified patients at low risk of recurrence and high bleeding risk. Sulodexide use for secondary prevention deserves further studies.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a žilní tromboembolie $x farmakoterapie $x epidemiologie $7 D054556
- 650 _2
- $a heparin nízkomolekulární $x škodlivé účinky $7 D006495
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a antikoagulancia $x terapeutické užití $7 D000925
- 650 _2
- $a krvácení $x chemicky indukované $x epidemiologie $7 D006470
- 650 _2
- $a fibrinolytika $7 D005343
- 650 _2
- $a aplikace orální $7 D000284
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Barinov, Victor $u Central State Medical Academy of the Office of the President of the Russian Federation, Volynskaya Clinical Hospital N.1, Moscow, Russia
- 700 1_
- $a Urbanek, Tomasz $u Medical University of Silesia, Katowice, Poland
- 700 1_
- $a Cini, Michela $u Arianna Anticoagulazione Foundation, Bologna, Italy
- 700 1_
- $a Li, Young-Jun $u Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
- 700 1_
- $a Bouslama, Kamel $u Faculty of Medicine of Tunis, Tunis, Tunisia
- 700 1_
- $a Matuška, Jiří $u Clinical Trial Centre, Hodonin, Czechia
- 700 1_
- $a Mansilha, Armando $u Faculty of Medicine, University of Porto, Porto, Portugal
- 700 1_
- $a Madaric, Juraj $u Clinic of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia
- 700 1_
- $a Sokurenko, German Y $u North-West Mechnikov State Medical University, St. Petersburg, Russia
- 700 1_
- $a Andreozzi, Giuseppe M $u Unit of Angiology, University of Padua, Padua, Italy
- 710 2_
- $a WHITE study group
- 773 0_
- $w MED00002267 $t International angiology : a journal of the International Union of Angiology $x 1827-1839 $g Roč. 42, č. 1 (2023), s. 37-44
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36714910 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141245 $b ABA008
- 999 __
- $a ok $b bmc $g 1924764 $s 1190497
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 42 $c 1 $d 37-44 $e 20230130 $i 1827-1839 $m International angiology $n Int Angiol $x MED00002267
- LZP __
- $a Pubmed-20230418
